Taysha Gene Therapies upgraded at Goldman Sachs on advancing Rett syndrome asset
Source: SeekingAlpha
2025-12-04 12:42:03 ET
More on Taysha Gene Therapies
- Taysha Gene Therapies, Inc. (TSHA) Q3 2025 Earnings Call Transcript
- Taysha Gene Therapies: Breakthrough Rett Program With BLA Acceleration Potential
- Taysha Gene Therapies: Shares Are Soaring On FDA Alignment, But Caution Is Advised
- Taysha outlines accelerated BLA timeline for TSHA-102 with FDA Breakthrough Therapy designation and full global rights
- Taysha Gene Therapies GAAP EPS of -$0.09 in-line
Read the full article on Seeking Alpha
For further details see:
Taysha Gene Therapies upgraded at Goldman Sachs on advancing Rett syndrome asset
Neurogene Inc.
NASDAQ: NGNE
NGNE Trading
-2.63% G/L:
$26.29 Last:
32,731 Volume:
$26.52 Open:
NGNE Latest News
April 28, 2026 07:30:00 am
Neurogene Announces Upcoming Presentation on the Therapeutic Rationale for ICV Delivery in CNS-Targeted Gene Therapy
April 20, 2026 07:30:00 am
Neurogene Appoints Christy Shafer as Chief Commercial Officer and Christine Mikail, J.D., to Board of Directors
April 04, 2026 06:40:44 am
Neurogene Inc. (NASDAQ:NGNE) Given Consensus Recommendation of "Moderate Buy" by Brokerages
March 24, 2026 07:30:00 am
Neurogene Reports Full Year 2025 Financial Results and Highlights Recent Updates
NGNE Stock Data
$263,326,600
13,686,787
0.57%
9
N/A
Pharmaceuticals
Healthcare
US
New York
